Ancestry invests in educating doctors about genetic testing
October 30, 2019 -- Ancestry is set to offer educational information on the interpretation of genetic testing results for physicians in early 2020 through a $1 million grant to UpToDate, a clinical decision-support tool from Wolters Kluwer.
IGeneX reports data for tick-borne fever test
October 30, 2019 -- Lyme disease specialist IGeneX has reported high sensitivity with a low risk for false positives in a study of its new immunoblot test for tick-borne relapsing fever.
PerkinElmer kicks off Vanadis prenatal testing
October 29, 2019 -- PerkinElmer announced that it is starting to process blood samples using its Vanadis noninvasive prenatal testing system for genetic anomalies at its CLIA lab in Pittsburgh and also at an affiliate lab in Kuala Lumpur, Malaysia.
Lineagen reports high accuracy for fragile X genetic test
October 29, 2019 -- Lineagen has reported that its DNA test for the developmental disorder fragile X syndrome has specificity and sensitivity close to 100% and could enable earlier diagnosis.
Roche Diagnostics appoints new CEO
October 28, 2019 -- Roche Diagnostics has appointed Matthew Sause as president and CEO of North American operations, effective November 4.
NYU Langone launches genetic profiling of brain tumors
October 28, 2019 -- NYU Langone Health announced that it has become the first CLIA-certified lab in the U.S. to get state approval to provide whole genome DNA methylation profiling for diagnosing and classifying brain tumors.
Hardy Diagnostics launches 15-minute resistance test
October 25, 2019 -- Hardy Diagnostics has launched a multiplex immunoassay for detecting the five most common carbapenemase enzymes produced by Enterobacteriaceae and Pseudomonas aeruginosa from bacterial cultures through a distribution deal with the assay's manufacturer, NG Biotech.
RNA testing clarifies the unknown in Ambry cancer study
October 25, 2019 -- RNA analysis helped clarify the significance of genetic variants associated with hereditary cancers that were inconclusive based on DNA testing alone in a retrospective study from Ambry Genetics published online October 23 in JAMA Network Open.
Myriad's myChoice PARP companion test clears FDA
October 24, 2019 -- Myriad Genetics' myChoice CDx has received U.S. Food and Drug Administration (FDA) premarket approval as a companion diagnostic to guide the use of GlaxoSmithKline's poly (ADP-ribose) polymerase (PARP) inhibitor niraparib (Zejula) in a new indication for heavily pretreated ovarian cancer.
LabCorp joins forces with Ind. nonprofit
October 24, 2019 -- LabCorp has acquired the diagnostic clinical laboratory assets of the Indiana-based nonprofit South Bend Medical Foundation (SBMF) and will be providing advanced pathology services to SBMF customers in the region as part of a new collaboration.